04:51 PM EDT, 04/02/2024 (MT Newswires) -- Adaptive Biotechnologies ( ADPT ) reported Tuesday that preliminary Q1 total revenue rose about 12% to $41 million to $43 million from a year earlier.

Analysts polled by Capital IQ expect $38.2 million.

Kyle Piskel was named chief financial officer, replacing Tycho Peterson, who is leaving to pursue another opportunity, the company said. Piskel had been principal accounting officer.

The company said its board and management team completed a strategic review and decided to operate minimal residual disease and immune medicine businesses internally.

Each business will have dedicated resources and separate segment reporting for increased independence, Adaptive said.

Price: 3.03, Change: +0.05, Percent Change: +1.68